Drug Approval | August 16, 2025
Zydus’ SEZ II, Ahmedabad plant clears USFDA inspection with nil observations
The inspection concluded with NIL observations
The inspection concluded with NIL observations
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
_256_384.jpg)
Marksans Pharma gets USFDA nod for acid reflux drug
Glenmark USA is named in multiple antitrust and consumer protection lawsuits, including class actions, consolidated in the Eastern District of Pennsylvania, U.S
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
The Q-Switched Nd:YAG system is suitable for all skin types and offers versatility in treating dermal and epidermal pigmentation
Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
This is the group’s first NoC approval in Canada
The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter
Subscribe To Our Newsletter & Stay Updated
